Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | EED | O75530 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25839004 | 0.80 | EED (0.41) | ALDH1A1SMN1; SMN2EEDMAPK1MEN1 | |
| SCHEMBL26677600 | 0.77 | KDM4E (0.51) | ALDH1A1KDM4ESMN1; SMN2HPGDMEN1 | |
| SCHEMBL18317031 | 0.77 | RIPK1 (0.47) | ALDH1A1KDM4ESMN1; SMN2HPGDMEN1 | |
| SCHEMBL29664382 | 0.74 | AKR1B1 (0.47) | ALDH1A1KDM4EHPGDEEDMEN1 | |
| SCHEMBL3827697 | 0.74 | AKR1B1 (0.47) | ALDH1A1KDM4EHPGDEEDMEN1 | |
| SCHEMBL15269326 | 0.73 | HPGD (0.54) | ALDH1A1KDM4ESMN1; SMN2HPGDMEN1 | |
| SCHEMBL23526395 | 0.72 | ALDH1A1 (0.38) | ALDH1A1KDM4ESMN1; SMN2MAPK1MEN1 | |
| SCHEMBL23042975 | 0.71 | ALDH1A1 (0.40) | ALDH1A1KDM4ESMN1; SMN2HPGDMEN1 | |
| SCHEMBL1953084 | 0.71 | PYCR1 (0.54) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL18421556 | 0.71 | HPGD (0.45) | ALDH1A1KDM4EHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023250165-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| EP-4076418-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| WO-2021127429-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | ALDH1A1 3260/4885KDM4E 3245/4885SMN1; SMN2 1579/4885 |
| US-20210188857-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | ALDH1A1 3367/4885KDM4E 2892/4885SMN1; SMN2 1762/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | ALDH1A1 3367/4885KDM4E 2892/4885SMN1; SMN2 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.